Document Detail

Nephrolithiasis in topiramate users.
MedLine Citation:
PMID:  21165738     Owner:  NLM     Status:  MEDLINE    
Topiramate is a neuromodulatory agent increasingly prescribed for a number of neurological and non-neurological indications. Topiramate-treated patients are at risk for nephrolithiasis due to hypocitraturia and high urine pH. However, the prevalence of symptomatic stone disease in TPM users is generally perceived to be low. This study was undertaken to assess in topiramate-treated patients the prevalence of symptomatic nephrolithiasis (by history) and of asymptomatic nephrolithiasis by computed tomography (CT) scan. Topiramate users were identified from a database of patients with neurological disorders at a single university hospital. Among 75 topiramate-treated adult patients with a median daily dose of 300 mg and median treatment duration of 48 months, the prevalence of symptomatic nephrolithiasis was 10.7%. In a subset of topiramate-treated patients and no history of symptomatic stone disease, the prevalence of asymptomatic nephrolithiasis detected by CT scan was 20%. The prevalence of symptomatic nephrolithiasis with long-term topiramate use is higher than reported in short-term studies. Furthermore, clinical prevalence is underestimated due to asymptomatic nephrolithiasis.
Naim M Maalouf; Joshua P Langston; Paul C Van Ness; Orson W Moe; Khashayar Sakhaee
Related Documents :
2288338 - The transcranial doppler ultrasonography in the evaluation of vasospasm and of intracra...
16179828 - Cerebral amyloid angiopathy with severe secondary vascular pathology: a histopathologic...
4089918 - Diagnosis of reversible versus irreversible cerebral ischemia by the intravenous admini...
12816268 - Leukocytosis as an independent risk factor for cerebral vasospasm following aneurysmal ...
3858788 - The serum apolipoprotein profile of patients with glucose-6-phosphatase deficiency.
7457698 - Gastric ph monitoring as a prognostic indicator for the prophylaxis of stress ulceratio...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-12-17
Journal Detail:
Title:  Urological research     Volume:  39     ISSN:  1434-0879     ISO Abbreviation:  Urol. Res.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-18     Completed Date:  2011-11-18     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  0364311     Medline TA:  Urol Res     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  303-7     Citation Subset:  IM    
Department of Internal Medicine, Charles and Jane Pak Center for Mineral Metabolism & Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8885, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fructose / adverse effects,  analogs & derivatives*
Middle Aged
Nephrolithiasis / chemically induced*,  epidemiology*
Neuroprotective Agents / adverse effects*
Prospective Studies
Retrospective Studies
Grant Support
Reg. No./Substance:
0/Neuroprotective Agents; 0H73WJJ391/topiramate; 30237-26-4/Fructose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development of individual differences in stress responsiveness: an overview of factors mediating the...
Next Document:  A Novel Antifungal Pseudomonas fluorescens Isolated from Potato Soils in Greenland.